1.96
0.02 (0.92%)
| Previous Close | 1.94 |
| Open | 1.99 |
| Volume | 16,398 |
| Avg. Volume (3M) | 153,159 |
| Market Cap | 50,754,400 |
| Price / Sales | 1.95 |
| Price / Book | 0.870 |
| 52 Weeks Range | |
| Earnings Date | 9 Aug 2024 - 13 Aug 2024 |
| Profit Margin | -85.75% |
| Operating Margin (TTM) | -748.92% |
| Diluted EPS (TTM) | -0.540 |
| Quarterly Revenue Growth (YOY) | -69.70% |
| Current Ratio (MRQ) | 10.68 |
| Operating Cash Flow (TTM) | -11.46 M |
| Levered Free Cash Flow (TTM) | -8.70 M |
| Return on Assets (TTM) | -21.35% |
| Return on Equity (TTM) | -36.01% |
AIStockmoo Score
| Value 38% | -1.7 |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Valuation History info | NA |
| Weak profitability. Ample short-term liquidity. Negative cash flow. info | |
| Return on Capital info | NA |
| Timing 38% | -4.6 |
| From our AI technical analysis of the chart. info | NA |
| Downtrend over the past year. Far below its 52-week high. info | |
| Candle Patterns info | NA |
| Trend for Your Holding Period info | NA |
| Sentiment 25% | 0.0 |
| No recent price targets, so based on how targets have been revised. info | |
| News Mood info | NA |
| Smart Money | NA |
| Insider Activity info | NA |
| Institutional Flow info | NA |
| Short Interest info | NA |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector lagging the market. | |
| The pillars agree, so the score is strengthened. | |
| Not in score | |
| Price is near its 52-week average. Down over 5 years. info | |
| No clear trend across the short, medium and long term. info | |
| Levels trending up. info | |
| Final Score | -3.31 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Ocuphire Pharma, Inc. | Mixed | Mixed |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| OCUP | 51 M | - | - | 0.870 |
| OPT | 583 M | - | - | 4.31 |
| CTMX | - | - | - | 1.55 |
| ZYME | - | - | - | 7.29 |
| PBYI | - | - | - | 2.73 |
| ORMP | - | 6.74% | - | 0.530 |
Select this tab to load the latest available analysis.
|
Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting the front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 6.11% |
| % Held by Institutions | 8.70% |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |